ABBOTT LABORATORIES 8-K

What Happened

• Abbott Laboratories (ABT) filed a Form 8-K on February 20, 2026 reporting that its Board of Directors amended the first sentence of Article III, Section 2 of the company's By-Laws to set the board size at twelve members, effective April 24, 2026.
• The By-Laws previously provided for a thirteen-person board. The company filed the amended and restated By-Laws (effective April 24, 2026) as an exhibit to the 8-K.

Key Details

• Board size change: from 13 directors to 12 directors.
• Board approval date (filing date): February 20, 2026.
• Effective date of change: April 24, 2026.
• Exhibit filed: Amended and restated By-Laws (Exhibit 3.1) effective April 24, 2026.

Why It Matters

• This is a corporate governance change affecting the composition of Abbott’s Board of Directors. The filing is limited to the By-Laws amendment and does not disclose other material changes (e.g., executive departures or financial results). Investors who monitor board composition and governance should note the change and the effective date.